Brokerages Set Evoke Pharma Inc. (EVOK) Target Price at $6.38
Shares of Evoke Pharma Inc. (NASDAQ:EVOK) have earned an average rating of “Hold” from the nine brokerages that are currently covering the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.38.
Several equities analysts have recently weighed in on EVOK shares. FBR & Co reissued an “outperform” rating and set a $9.00 target price on shares of Evoke Pharma in a research report on Sunday, July 31st. Noble Financial reissued a “hold” rating on shares of Evoke Pharma in a research report on Tuesday, August 16th. HC Wainwright set a $2.50 target price on Evoke Pharma and gave the company a “hold” rating in a research report on Tuesday, August 16th. Finally, Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Wednesday, October 5th.
Several large investors have recently modified their holdings of EVOK. State Treasurer State of Michigan boosted its stake in shares of Evoke Pharma by 460.0% in the third quarter. State Treasurer State of Michigan now owns 140,000 shares of the specialty pharmaceutical company’s stock valued at $316,000 after buying an additional 115,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Evoke Pharma by 5.0% in the second quarter. Vanguard Group Inc. now owns 62,381 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,947 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Evoke Pharma by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 23,679 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 464 shares in the last quarter. Institutional investors and hedge funds own 9.15% of the company’s stock.
Evoke Pharma (NASDAQ:EVOK) opened at 1.76 on Monday. The stock’s market cap is $21.74 million. Evoke Pharma has a 12 month low of $1.35 and a 12 month high of $11.11. The firm’s 50-day moving average price is $1.86 and its 200 day moving average price is $3.61.
Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. During the same quarter in the previous year, the company earned ($0.42) earnings per share. On average, analysts anticipate that Evoke Pharma will post ($1.32) earnings per share for the current year.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.